Supply Agreement for Cardiomyopathy Treatment API with BridgeBio Pharma

Contract amount: approx. 55.99 billion KRW (USD 38,076,000, at 1,470.5 KRW/USD)
Contract period: 2026-05-05 to 2028-03-01 (about 22 months)
2.56% of total revenue (based on 2025 consolidated revenue of 2.18 trillion KRW)
Counterparty: BridgeBio Pharma, Inc. (US biotech firm)
Payment terms: net 30 days from invoice, no upfront payment
Sales region: undetermined

ADVERTISEMENT (250px+)